Evolent Health (EVH) In Sale Talks After Inbound Interest - Reuters

Go back to Evolent Health (EVH) In Sale Talks After Inbound Interest - Reuters

Truist Securities Reiterates Buy Rating on Evolent Health (EVH)

August 23, 2024 7:02 AM UTC

Truist Securities analyst Jailendra Singh reiterated a Buy rating and $33.00 price target on Evolent Health (NYSE: EVH).

The analyst comments "Bottom Line. M&A discussions related to EVH, whether in part of whole, is not a foreign discussion to the company. However, we... More

Piper Sandler Reiterates Overweight Rating on Evolent Health (EVH)

August 22, 2024 3:59 PM UTC

Piper Sandler analyst Jessica Tassan reiterated an Overweight rating and $38.00 price target on Evolent Health (NYSE: EVH).

The analyst comments "Reuters reports that EVH is weighing sale, following takeover interest. The publication states that EVH has received initial offers and that potential acquirers could include PE firms or ELV (not covered) in combination with a PE partner. Our thoughts on today's news. 1. EVH is defining and dominating the market for value-based specialty care management. This is a $732B TAM which we define our white paper on the space here. 2. EVH has assembled best-in-class... More

BTIG Reiterates Buy Rating on Evolent Health (EVH)

August 22, 2024 3:57 PM UTC

BTIG analyst David Larsen reiterated a Buy rating and $45.00 price target on Evolent Health (NYSE: EVH)

The analyst comments "Shares of EVH are trading up due to an article in Reuters, stating that several private equity firms, and at least one large health plan, are in discussions to potentially acquire EVH. The press report highlights that a process started after EVH received in-bound... More